drugset
drugset / Trial / NCT05795192

SB17170 Phase1 Trial in Healthy Volunteer

NCT05795192 ↗

Phase 1 Completed 64 enrolled SPARK Biopharma
RandomizedParallel-groupDouble-blindTreatment

Summary

This clinical trial aims to learn about the safety, tolerability, and pharmacokinetic properties of SB17170 and its active metabolite SB1703 in single and multiple oral administration in healthy adults. The main questions it aims to answer are the safety, tolerability, and PK characteristics of SB17170 in healthy adults.

Timeline

Start
2023-05-24
Primary completion
2024-02-29
Completion
2024-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject SB17170 Unknown 50 mg Oral
Subject SB17170 Unknown 150 mg Oral
Subject SB17170 Unknown 250 mg Oral
Subject SB17170 Unknown 500 mg Oral
Subject SB17170 Unknown 1000 mg Oral
Subject SB17170 Unknown 1500 mg Oral

Indications

No indication recorded.